Department of Urology, St. Antonius Hospital, Gronau, Germany.
Anticancer Res. 2010 May;30(5):1735-9.
Although the NWTSG and SIOP studies have included the largest number of patients, several individual institutions have made likewise important contributions to the optimization of Wilms' tumor therapy. The purpose of this study is to present our personal experience obtained in the last 42 years by treating Wilms' tumor in childhood.
Throughout the period 1965-2006, 65 children with histological confirmation of Wilms' tumour were treated in the Department of Urology, University of Erlangen Medical Centre. The records of all patients presenting to our institution with Wilms' tumour were examined.
The results obtained by this study group indicate that prognosis according to age demonstrated no significance, but prognosis according to tumor size, lymph node involvement and distant metastasis was significant. After a 10-year follow-up, our data revealed an 89.4% survival rate. Furthermore, the statistical evaluation performed in order to evaluate the significance of surgical complications following neoadjuvant therapy in comparison to non adjuvant therapy, indicates that there is a significant increase in complications in patients who are not treated with neoadjuvant therapy.
Although clinicians in the U.S.A. and Europe have different philosophies on preoperative chemotherapy, most patients with Wilms' tumor survive long term, regardless of the sequence of therapeutic interventions. In the absence of a clear choice between up-front nephrectomy and preoperative chemotherapy, it is reasonable to base the timing of resection on factors such as tumor size, the patient's clinical condition, and the experience of the surgeon.
尽管 NWTSG 和 SIOP 研究纳入了数量最多的患者,但一些个别机构也为优化肾母细胞瘤治疗做出了同样重要的贡献。本研究旨在介绍我们在过去 42 年中治疗儿童肾母细胞瘤的个人经验。
在 1965 年至 2006 年期间,65 例经组织学证实为肾母细胞瘤的患儿在埃尔朗根大学医学中心泌尿外科接受治疗。对所有在我院就诊的肾母细胞瘤患者的记录进行了检查。
本研究组的结果表明,按年龄分组的预后无显著意义,但按肿瘤大小、淋巴结受累和远处转移分组的预后有显著意义。经过 10 年的随访,我们的数据显示生存率为 89.4%。此外,为评估新辅助治疗后与非辅助治疗相比手术并发症的意义而进行的统计评估表明,未接受新辅助治疗的患者并发症明显增加。
尽管美国和欧洲的临床医生在术前化疗方面有不同的理念,但大多数肾母细胞瘤患者都能长期存活,无论治疗干预的顺序如何。在没有明确选择 upfront 肾切除术和术前化疗之间的情况下,根据肿瘤大小、患者的临床状况和外科医生的经验等因素来确定切除的时机是合理的。